Targeted Deletion of Peroxiredoxin 1 Enhances Anti‐Tumor Immunity in Colorectal Cancer by Reprogramming the Immunosuppressive Tumor‐Associated Macrophages. This evidence concerns the gene PRDX1 and neoplasm.